Pictet Asset Management (Switzerland)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$37.2M	Sell	5,286,536 -331,836	-6%	-$2.66M	0.04%	345
2023 Q1	$46.9M	Buy	5,618,372 +333,024	+6%	+$3.21M	0.06%	294
2022 Q4	$60.7M	Buy	5,285,348 +471,576	+10%	+$5.88M	0.09%	242
2022 Q3	$60.7M	Sell	4,813,772 -1,233,189	-20%	-$15.9M	0.09%	243
2022 Q2	$64M	Buy	6,046,961 +940,058	+18%	+$9.7M	0.09%	246
2022 Q1	$83M	Buy	5,106,903 +51,639	+1%	+$828K	0.09%	243
2021 Q4	$70M	Buy	5,055,264 +5,043,299	+42,150%	+$66.7M	0.07%	286
2021 Q3	$172K	Buy	+11,965	New	+$189K	﹤0.01%	1639

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s BCRX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its BioCryst Pharmaceuticals (BCRX) stake by 5.9% in Q2 2023, selling an estimated $2.66M and leaving 5,286,536 shares worth $37.2M. The position accounts for 0.04% of the portfolio, ranked #345.

Pictet Asset Management (Switzerland) first reported a position in BCRX in Q3 2021 and has held it in 8 quarters since. The position peaked at $83M in Q1 2022. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

Pictet Asset Management (Switzerland) held 5,286,536 shares of BioCryst Pharmaceuticals worth $37.2M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 331,836 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $2.66M.
BioCryst Pharmaceuticals made up 0.04% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #345 holding.
Pictet Asset Management (Switzerland) first reported a position in BioCryst Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s BioCryst Pharmaceuticals position peaked at $83M in Q1 2022.
236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.